Peptides Codex
ENFR
← Home
Ghrelin receptor agonist (orally active)

Anamorelin

Anamorelin is an orally active, centrally penetrant agonist of the ghrelin/growth hormone secretagogue receptor with appetite-stimulating and anabolic properties. It has been studied for cancer-associated cachexia; the European Medicines Agency declined marketing authorization in 2017, and it is not authorized by Health Canada. This page is educational and is not medical advice.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
n/a
Class
Ghrelin receptor agonist (orally active)
Function
Growth hormone secretagogue receptor agonist
Context
Investigated for cancer-associated cachexia; the EMA declined marketing authorization in 2017 and it is not authorized by Health Canada

An oral ghrelin mimetic studied in cancer cachexia for appetite and lean-mass effects.

Also known as: ONO-7643 · RC-1291 · ghrelin receptor agonist

Part of the Growth hormone & IGF peptides cluster

Overview

Anamorelin is an orally active, centrally penetrant agonist of the ghrelin/growth hormone secretagogue receptor with appetite-stimulating and anabolic properties. It has been studied for cancer-associated cachexia; the European Medicines Agency declined marketing authorization in 2017, and it is not authorized by Health Canada. This page is educational and is not medical advice.

Source & context

Biological / chemical source: Synthetic orally active small-molecule ghrelin mimetic

Primary research or clinical context: Investigated for cancer-associated cachexia; the EMA declined marketing authorization in 2017 and it is not authorized by Health Canada

Cachexia research focus

Cancer cachexia involves involuntary loss of weight and muscle. Anamorelin was evaluated for its ability to increase appetite and lean body mass, though regulators noted questions about the size and clinical meaningfulness of measured effects.

Ghrelin-mimetic class

Anamorelin activates the same receptor targeted by ghrelin and by peptide GH secretagogues. It is often discussed alongside macimorelin and relamorelin as an orally active member of the broader secretagogue conversation.

FAQ about Anamorelin

What is Anamorelin?+

Anamorelin is an orally active, centrally penetrant agonist of the ghrelin/growth hormone secretagogue receptor with appetite-stimulating and anabolic properties. It has been studied for cancer-associated cachexia; the European Medicines Agency declined marketing authorization in 2017, and it is not authorized by Health Canada. This page is educational and is not medical advice.

Is Anamorelin an approved medicine?+

Anamorelin is discussed here as a research / educational topic. Investigated for cancer-associated cachexia; the EMA declined marketing authorization in 2017 and it is not authorized by Health Canada. This is not medical advice.

What is the typical length of Anamorelin?+

Anamorelin is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.

Related peptides

PE-22-28
Research peptide
PE-22-28 is a synthetic heptapeptide derived from spadin, developed as a shortened analog that inhibits the TREK-1 potassium channel. It has been examined in rodent neuroscience studies and is not authorized as a medicine by Health Canada.
Cortexin
Polypeptide complex
Cortexin is a low-molecular-weight polypeptide complex extracted from cerebral cortex tissue, studied largely in Russian neuroscience literature. It is marketed as a drug in some countries but is not authorized by Health Canada.
Pinealon
Research peptide
Pinealon is a synthetic tripeptide (Glu-Asp-Arg, EDR) from the Khavinson short-peptide bioregulator class. It has been studied for proposed neuroprotective and gene-regulatory effects in mostly Russian laboratory research and is not authorized as a medicine by Health Canada.
Teverelix
GnRH antagonist (decapeptide analog)
Teverelix is a synthetic decapeptide GnRH antagonist that binds competitively and reversibly to pituitary GnRH receptors, suppressing luteinizing hormone and follicle-stimulating hormone. It is an investigational compound studied in prostate disorders and is not authorized by Health Canada. This page is educational and is not medical advice.

References & further reading

  1. 1.Wikipedia — Anamorelin
  2. 2.PubChem — compound summary for Anamorelin (CID 9828911)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Anamorelin educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.